re: Data Monitoring Committee meeting on Oct. 17.
I'm new to CPRX, but like what I've seen and studied so far. A couple general questions:
1. What outcome can we expect from the DMC next month?
2. What are the possible scenarios from the DMC meeting that could affect the pps?
If all goes well, it looks like the company is sitting pretty for March, closure to the Firdapse trial, and top-line results soon thereafter. However, right now I am evaluating the risks of holding through this near term catalyst in October.
Thanks for your objective replies and GL to all.